Berman tabacco investigates potential securities law violations by california-based fibrogen inc. (fgen) in connection with roxadustat "clarification"

San francisco, california--(newsfile corp. - april 8, 2021) - berman tabacco, a national law firm representing investors, is investigating potential securities law claims against fibrogen inc. (nasdaq: fgen) ("fibrogen" or the "company"). fibrogen is a biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("ckd").on november 8, 2019, the company issued a press release announcing, "positive phase 3 pooled roxadustat safety and efficacy results for treatment of anemia in chronic...
FGEN Ratings Summary
FGEN Quant Ranking